A detailed history of Bessemer Group Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 33 shares of ALNY stock, worth $8,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33
Holding current value
$8,027
% of portfolio
0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$233.81 - $287.01 $7,715 - $9,471
33 New
33 $9,000
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $17,930 - $22,223
105 Added 28.3%
476 $84,000
Q2 2023

Aug 10, 2023

BUY
$185.01 - $212.05 $68,638 - $78,670
371 New
371 $70,000
Q3 2022

Nov 09, 2022

BUY
$138.54 - $232.0 $11.7 Million - $19.5 Million
84,256 Added 351066.66%
84,280 $16.9 Million
Q2 2022

Aug 10, 2022

BUY
$120.42 - $169.29 $2,890 - $4,062
24 New
24 $4,000
Q4 2021

Jan 27, 2022

SELL
$159.56 - $209.29 $6,222 - $8,162
-39 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $6,620 - $8,101
39 New
39 $7,000
Q2 2021

Aug 06, 2021

SELL
$128.63 - $176.89 $99,173 - $136,382
-771 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$126.83 - $175.69 $7,990 - $11,068
63 Added 8.9%
771 $108,000
Q4 2020

Feb 09, 2021

SELL
$122.97 - $147.0 $36,891 - $44,100
-300 Reduced 29.76%
708 $92,000
Q3 2020

Nov 12, 2020

SELL
$121.19 - $165.49 $24,238 - $33,098
-200 Reduced 16.56%
1,008 $147,000
Q2 2020

Aug 05, 2020

BUY
$104.21 - $156.44 $125,885 - $188,979
1,208 New
1,208 $179,000
Q2 2019

Jul 19, 2019

SELL
$65.86 - $92.79 $3,293 - $4,639
-50 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$72.76 - $93.45 $2,401 - $3,083
-33 Reduced 39.76%
50 $5,000
Q4 2018

Feb 12, 2019

BUY
$62.67 - $88.33 $5,201 - $7,331
83 New
83 $6,000
Q4 2017

Jan 30, 2018

SELL
$114.49 - $139.98 $20,035 - $24,496
-175 Closed
0 $0
Q3 2017

Nov 03, 2017

BUY
$72.53 - $118.27 $12,692 - $20,697
175
175 $21,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.